SPL-891.1

SPL-891.1 (also known as GTI-891.1) is a small molecule inhibitor of S-nitrosoglutathione reductase (GSNOR) being developed by GSNOR Therapeutics. GSNOR is an enzyme that regulates the levels of S-nitrosoglutathione (GSNO), a key signaling molecule in nitric oxide (NO) biology. By inhibiting GSNOR, SPL-891.1 aims to increase GSNO levels, thereby enhancing S-nitrosylation and modulating various inflammatory and fibrotic pathways. The drug is currently in preclinical development for a wide range of indications, including idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), rheumatoid arthritis, diabetes, Crohn's disease, heart failure, stroke, and neurodegenerative disorders. It has been studied across multiple routes of administration, including oral, intravenous, intraperitoneal, and intravitreal.

Other names

SPL-891.1SPL891.1SPL 891.1GTI-891.1GTI891.1GTI 891.1